Adjuvant recombinant thrombomodulin therapy for hepatopathy induced by vincristine, actinomycin D, and cyclophosphamide in pediatric rhabdomyosarcoma: A case report

Abstract

Hepatopathy induced by vincristine, actinomycin D and cyclophosphamide (VAC) is a potentially lethal complication of VAC chemotherapy for pediatric malignancy, which is managed by conventional anticoagulation and liver-supporting treatment alone. We report a case of VAC-induced hepatopathy with coagulopathy and severe inflammation. A 15-year-old male with rhabdomyosarcoma receiving adjuvant chemotherapy presented with refractory thrombocytopenia, followed by abdominal tenderness and non-neutropenic fever. Hepatic dysfunction and coagulopathy subsequently emerged with persistent fever. This condition indicated disseminated intravascular coagulation. A diagnosis of ‘very severe’ sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) was established in accordance with the European Society for Blood and Marrow Transplantation diagnostic criteria for hepatic SOS/VOD in children. Early administration of recombinant thrombomodulin (rTM) (380 U/kg/day) and prednisolone (1.8 mg/kg/day) successfully controlled the condition. Serum concentrations of pro-inflammatory cytokines increased with hepatopathy development but immediately decreased after drug initiation. rTM administration may be promising for the control of inflammatory VAC-induced hepatopathy.

Introduction

Hepatopathy induced by vincristine, actinomycin D, and cyclophosphamide (VAC) is a potentially lethal complication of VAC chemotherapy for pediatric malignancy, including rhabdomyosarcoma (RMS), empirically managed by conventional anticoagulation therapy and liver-supporting agents. VAC-induced hepatopathy is pathophysiologically similar to sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in the transplant setting, in which the primary insult is injury to the sinusoidal endothelial cells triggered by anticancer drug toxicity and proinflammatory cytokine release (1). The incidence rate of VAC-induced hepatopathy in RMS has been reported to be 1.2–15.4% (2–4). More efficient management than the current empirical one is required to avoid threat to life and minimize delays and dose reduction in chemotherapy. Thrombomodulin is a thrombin receptor on the endothelial cell surface. Recombinant thrombomodulin (rTM) consists of the active extracellular domain of thrombomodulin, including the N-terminal lectin-like domain with unique anti-inflammatory properties (5,6). In particular, rTM administration exerts beneficial effects on the control of transplantation-associated thrombotic microangiopathy and SOS/VOD resulting from endothelial damage, coagulability, and exaggerated cytokine production (7). Nevertheless, the effect of rTM in VAC-induced hepatopathy remains unknown owing to the absence of reports.

We presented here a pediatric case of VAC-induced hepatopathy associated with coagulopathy and inflammation that was successfully controlled by the administration of rTM and conventional dose of prednisolone. The pathogenesis and management of VAC-induced hepatopathy with inflammatory cytokine profile were discussed in concert with the treatment response and literature review. Consent for publication of the case report was obtained from the patient and his mother.

Case report

Fig. 1 shows the timeline. A-15-year-old male with paratesticular RMS exhibiting no evidence of metastasis to other organs, including the liver, received adjuvant chemotherapy comprising four cycles of VAC (total cumulative dose of cyclophosphamide, 4.8 g/m²) followed by four cycles of vincristine and actinomycin D with a total duration of 22 weeks with or without local radiation therapy (8). He had no personal and family history of injury or illness. During the 13th week of schedule for adjuvant chemotherapy from which the first cycle of vincristine and actinomycin D started after four cycles of VAC, he presented with refractory thrombocytopenia, along with subsequent abdominal tenderness and non-neutropenic fever. He was treated empirically with broad-spectrum intravenous antibiotics (cefepime) and continuously with platelet transfusion.

Figure 1.

Treatment course and cytokine levels of the patient. AC, actinomycin D and cyclophosphamide; VA, vincristine and actinomycin D; V, vincristine; Plt, platelet; WBC, white blood cell; AST, aspartate transaminase; ALT, alanine transaminase; T-Bil, total bilirubin; CRP, C-reactive protein; TNFα, tumor necrosis factor-α; IL-1β, interleukin-1β; IL-6, interleukin-6; rTM, recombinant thrombomodulin; PSL, prednisolone; AT3, antithrombin III; UDCA, ursodeoxycholic acid.

At day 3 of the 14th week (at 10 days after administration of vincristine and actinomycin D or at 2 days after administration of vincristine alone), full-blown hepatic dysfunction and coagulopathy were noted, along with persistent fever up to 39.6°C (leukocyte count, 8.37×10⁹/l; hemoglobin, 8.1 g/dl; platelet count, 18×10⁹/l; fibrinogen, 305 mg/dl; prothrombin time-international normalized ratio, 1.82; antithrombin III, 73%; fibrin/fibrinogen degradation products, 20.18 µg/ml; aspartate transaminase [AST], 1961 U/l; alanine aminotransferase [ALT], 1084 U/l; total bilirubin [T-Bil], 2.1 mg/dl; C-reactive protein [CRP], 4.52 mg/dl; ferritin, 17,968 ng/ml). This condition fulfilled the diagnostic criteria for disseminated intravascular coagulation (DIC) (9) and was strongly suggestive of hemophagocytic lymphohistiocytosis (HLH) (four of eight items met the Histiocyte Society HLH-2004 criteria, with highly elevated ferritin level) (10,11). Furthermore, the diagnostic criteria for ‘very severe’ SOS/VOD were met in accordance with the European Society for Blood and Marrow Transplantation diagnostic criteria for hepatic SOS/VOD in children (1). At this stage, we initiated the administration of rTM (380 U/kg/day) to control DIC on the basis of absent hemorrhagic diathesis and of prednisolone (PSL) (1.8 mg/kg/day) to control HLH, with supportive therapies including blood transfusion; administration of ulinastatin, antithrombin III, and L-cysteine; and strengthened antibacterial therapy (to add amikacin sulfate).

His condition improved after the therapy, with defervescence and amelioration of abdominal pain. Levels of T-Bil, AST, ALT, and CRP improved after peaking at 2.7 mg/dl, 1,963 U/l, 1,292 U/l, and 5.5 mg/dl, respectively, on the subsequent day of rTM and PSL therapy. Furthermore, levels of coagulation markers and serum ferritin rapidly improved. The first abdominal Doppler ultrasonography performed at 2 days after rTM and PSL administration revealed bidirectional blood flow of the left portal vein. His body weight increased by 7% above the baseline value. Results of hepatitis virus panel were negative, and blood cultures were sterile. Liver biopsy for pathological confirmation was not performed in consideration of thrombocytopenia and coagulopathy. After day 7 of rTM therapy, the schedule for radio- and chemotherapy was restarted at 1 week later with the dose of vincristine in full and actinomycin D in half. Although the patient had two episodes of isolated fever during vincristine administration, severe hepatopathy with inflammation and coagulopathy never recurred. PSL was started to be tapered and finished at 1 month later. He is alive and well on disease-free state of RMS at the age of 16 years and 6 months.

Serum concentrations of proinflammatory cytokines were measured using an established method by LSI Medience Corporation (Tokyo, Japan) with kits from R&D Systems, Inc. (Minneapolis, MN, USA). The levels of tumor necrosis factor-α (TNF-α) (QuantiGlo ELISA Human TNF-α Immunoassay with a lower detection limit of 0.55 pg/ml: Non-detectable [ND] to 9.03 pg/ml in healthy volunteers), interleukin-1β (IL-1β) (Quantikine HS ELISA Human IL-1β/IL-1F2 Immunoassay with a lower detection limit of 0.125 pg/ml: ND to 0.606 pg/ml in healthy volunteers), and interleukin-6 (IL-6) (QuantiGlo ELISA Human IL-6 Immunoassay with a lower detection limit of 0.30 pg/ml: ND to 5.84 pg/ml in healthy volunteers) were as follows: 1.84, <0.125, and 7.25 pg/ml at day 5 of the 13th week (before the event); 2.82, 0.458, and 363 pg/ml at day 3 of the 14th week (day of rTM and PSL therapy initiation before administration); and 1.76, <0.125, and 46.8 pg/ml at day 5 of the 14th week (2 days after rTM and PSL therapy initiation), respectively. The cytokine profile showed an increase with hepatopathy development and a decrease immediately after drug initiation.

Discussion

SOS/VOD is a life-threatening complication of anticancer drug administration that was originally identified as a transplant-related endothelial disease. In the liver, recruited monocytes/macrophages and resident Kupffer cells are thought to play important roles on the insulted sinusoidal walls (12,13), with activated Kupffer cells having been confirmed to secrete IL-1β, IL-6, and TNF-α (14–16).

Particularly in children, SOS/VOD can also occur as a complication of conventional radio- and chemotherapy outside of the transplant setting with recurrent association with actinomycin D, vincristine, cyclophosphamide, and 6-mercaptopurine (1). There was little recognition of the risk of VAC-induced hepatopathy among children with RMS until the case report of Kanwar et al (17). Subsequently, a clinical trial performed by the Intergroup Rhabdomyosarcoma Study Group reported an incidence rate of 5.3% (4). Table I shows hepatopathy in conventional chemotherapy regimen for RMS (2–4,18–22). Most cases were supportively managed mainly by conventional anticoagulation. Therapies targeting inflammation have scarcely been reported to date. One case was reported to be treated with high-dose methylprednisolone. Although the patient recovered, the condition continued to worsen up to 4 days after therapy initiation (22). Defibrotide, which protects the endothelial cells from continued damage due to cytotoxic drugs and TNF-α, was shown to be a feasible therapeutic option for both transplant- and non-transplant-associated SOS/VOD (23). In a review, when defibrotide was administered in two patients, one died, whereas the other recovered after intensive care including ventilatory support (4,23). Nonetheless, defibrotide is yet to be licensed for clinical use in Japan.

Table I.

VAC-induced hepatopathy in rhabdomyosarcoma reviewed.

Age, year	Sex	Tumor site	Therapy for hepatotherapy other than supportive carea	Duration of hepatotherapy	Outcome of hepatotherapy	Further therapy	Outcome of RMS	(Refs.)
0.3					R	VIC/VTC	NED	(4)
1	M	Thigh	Gabexate mesilate	1 month	R	VAC	NED	(19)
1.1			Defibrotide		Dead		Dead	(4)
1.5					R	VAC	NED	(4)
1.7					R	Off	NED	(4)
1.7			Ventilator		Dead		Dead	(4)
1.8					R	VIE	NED	(4)
1.8	M	Face	High-dose methylprednisolone	3–4 weeks	R	VECb	NED	(22)
2	M	Face	Abdominal paracentesis	2 weeks	R	VIE	NED	(21)
2.3			Ventilator		R	VTC/VIE	NED	(4)
2.4					R	Off	NED	(4)
2.7			Ventilator		R	VIE	NED	(4)
2.7					R	VIE	NED	(4)
3.8					R	VAC	NED	(4)
3.8	F	Head	Thoracentesis, activated factor IX	>1 month	Left	VIE	NED	(17)
			concentrate, ventilator		ptosis
4.0			Ventilator		R	VIE	NED	(4)
4.7					Dead		Dead	(4)
5.0					Dead		Dead	(4)
6.1					R	Off	NED	(4)
9	F	Limb	Defibrotide, abdominal paracentesis,		R	Off	NED	(23)
			ventilator
12.9					R	VIE	Relapse	(4)
14.3					R	VAC	NED	(4)
15.5		Para	rTM, PSL	1 week	R	VAC	NED	Index
		testicular						case
17.9					R	VAC	NED

^aSupportive care included body fluid and electrolyte correction, blood transfusion, heparin, antithrombin III, liver-supporting agent, and antibiotics. bE means epirubicin only here; other Es mean etoposide. RMS, rhabdomyosarcoma; M, male; F, female; V, vincristine; A, actinomycin D; C, cyclophosphamide; I, ifosfamide; E, etoposide; T, topotecan; G-CSF, granulocyte colony-stimulating factor; rTM, recombinant thrombomodulin; PSL, prednisolone; R, recover; NED, no evidence of disease.

Our case indicated the marked hyperferritinemia, which was substantiated with hypercytokinemia, as severe inflammation. We used a combination of rTM and PSL, and all of the patient's symptoms and laboratory data, including pro-inflammatory cytokine profile, immediately improved after the administration of these drugs. rTM itself has been reported to have a unique anti-inflammatory property by binding to high-mobility group box 1 protein (HMGB1), which is secreted by activated monocytes and macrophages (6,24). However, the effect of systemic corticosteroid treatment was observed to be confined to reduction in extracellular HMGB1 expression, but not in intracellular expression (25). Kurokohchi et al (26) reported that rTM-but not corticosteroid-for fulminant hepatic failure, which is also characterized by severe liver inflammation, was sufficiently effective. From the viewpoint of relatively long duration before withdrawal and various side effects, corticosteroid use is best avoided, if possible. In addition, although the in vitro anti-inflammatory effect of ulinastatin has been shown (27), its effect on liver inflammation in the clinical setting has not yet been reported.

We presume that rTM could ameliorate not only coagulopathy but also excessive inflammation via suppression of proinflammatory cytokines. As a novel treatment for VAC-associated hepatopathy with inflammatory profile, rTM could become promising for reducing treatment-related mortality and, more substantially, minimizing delays and dose reduction in chemotherapy for RMS.

Glossary

Abbreviations

VAC

vincristine, actinomycin D, and cyclophospha-mide

SOS/VOD

sinusoidal obstruction syndrome/veno-occlusive disease

rTM

recombinant thrombomodulin

AST

aspartate transaminase

ALT

alanine aminotransferase

T-Bil

total bilirubin

CRP

C-reactive protein

DIC

disseminated intravascular coagulation

HLH

hemophagocytic lymphohistiocytosis

PSL

prednisolone

TNF-α

tumor necrosis factor-α

ND

non-detectable

IL-1β

interleukin-1β

IL-6

interleukin-6

HMGB1

high-mobility group box 1 protein

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

TK analyzed the medical records of the patients, measured cytokine levels of the patient and was the principal writer primarily responsible for drafting the manuscript. MN, HN and RF were responsible for the clinical management of the patient with helpful discussion for the completion of the study. RF created the high-resolution figure. HN supervised the project. SO interpreted the data collected by TK, was involved in drafting the manuscript critically for important intellectual content and supervised the conduct of the present study.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

General consent for research including publication of the case report was obtained from the patient and his mother.

Competing interests

The authors declare that they have no competing interests.